Moderna Cancer Vaccine Trial Sends Shares Soaring Higher

NEW YORK: (News Desk) – Moderna shares surged after the biotechnology company and Merck & Co. reported positive preliminary results from a late-stage trial of their experimental personalized cancer vaccine, marking a potentially important milestone for mRNA-based cancer treatment.

The vaccine is being developed by Moderna in partnership with Merck and is being tested alongside Keytruda, Merck’s widely used cancer immunotherapy. Unlike conventional preventive vaccines, the experimental treatment is designed to be tailored to each patient based on genetic mutations identified in their individual tumor.

The Phase III trial involved more than 1,100 patients with stage IIIc melanoma, all of whom had undergone surgery to remove their tumors before entering the study.

According to the companies, the combination of the personalized vaccine and Keytruda met its primary goal by helping delay both cancer recurrence and the spread of the disease to other parts of the body.

Moderna and Merck also reported that the trial did not reveal any new safety concerns associated with the vaccine or Keytruda. More detailed findings are expected to be presented at a future scientific meeting before the companies submit the complete data to regulatory authorities.

Moderna shares jump

Investors responded strongly to the announcement, with Moderna shares rising more than 90% in pre-market trading. Merck’s stock also moved higher following the news.

The market reaction reflects expectations that a successful personalized cancer vaccine could give Moderna a major opportunity to expand beyond its COVID-19 vaccine business and establish its mRNA technology in oncology.

The companies have described the Phase III results as the first successful late-stage demonstration of an mRNA-based personalized cancer treatment, potentially marking a significant moment for the wider field.

How the personalized vaccine works

Cancer vaccines differ from traditional vaccines because they are designed to help the immune system identify and attack existing cancer cells, rather than protect against an infectious disease before exposure.

To develop a personalized treatment, researchers analyse the genetic mutations found in an individual patient’s tumor. Scientists then use that information to create an mRNA vaccine designed to teach the immune system to recognise specific characteristics of the patient’s cancer cells.

This approach means the treatment can be customized to an individual patient rather than providing the same vaccine formulation to everyone.

Earlier research showed promise

The latest findings build on encouraging results from earlier research. Five-year follow-up data from an early-stage study previously indicated a statistically significant reduction in melanoma recurrence among patients who received the personalized vaccine with Keytruda compared with those treated with Keytruda alone.

The experimental vaccine, intismeran autogene, however, remains an investigational treatment and has not been approved by the US Food and Drug Administration (FDA).

Moderna and Merck are expected to provide regulators with the complete Phase III results after the study data have been fully analysed. Regulatory review and approval would be required before the treatment could become routinely available to patients.

The successful completion of the Phase III trial therefore represents a major development in the vaccine’s clinical programme, but does not mean doctors can currently prescribe it as an approved cancer treatment.